The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Market Value Expansion Is Expected For The Omics-Based Clinical Trials Market Over The Forecast Period?
The omics-based clinical trials market size has experienced robust growth recently. This market is projected to expand from $31.71 billion in 2025 to $34.49 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. Historically, this expansion has been driven by factors such as the increasing intricacy of clinical trial designs, the surge in genomic and proteomic research, a growing need for personalized therapies, the broadening of clinical research infrastructure, and enhanced partnerships between pharmaceutical companies and academic bodies.
The omics-based clinical trials market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $47.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Key factors driving this growth during the forecast period include the escalating adoption of precision medicine approaches, a surge in investments towards data-driven clinical trials, the broadened use of AI for patient recruitment, increasing regulatory approval for omics-based endpoints, and a heightened need for effective trial outcomes. Significant trends observed in the forecast period encompass the wider embrace of biomarker-driven trial designs, an increase in the application of multi-omics for patient stratification, the expanding incorporation of real-world evidence analytics, the growth of precision oncology clinical trials, and an intensified concentration on data-centric approaches for trial optimization.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp
What Primary Factors Are Fueling The Expansion Of The Omics-Based Clinical Trials Market?
The escalating need for personalized medicine is projected to drive the expansion of the omics-based clinical trials market in the coming years. Personalized medicine describes a medical strategy that customizes disease prevention, diagnosis, and treatment according to the distinct characteristics of each individual patient. The increasing demand for personalized medicine stems from advancements in genomic technologies, which facilitate quicker, more economical analysis of individual genetic profiles to guide specific treatments. Omics-based clinical trials bolster personalized medicine by enabling the identification of individual genetic, proteomic, and metabolic profiles, thereby allowing for more targeted and effective treatment strategies precisely tailored for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. This figure represents an increase from six approvals in 2022, with the 2023 approvals further comprising seven oncology therapies and three treatments addressing various other conditions. Consequently, the rising demand for personalized medicine is a significant impetus behind the growth of the omics-based clinical trials market.
How Is The Omics-Based Clinical Trials Market Structured Across Different Market Segments?
The omics-based clinical trials market covered in this report is segmented –
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling
Which Trends Are Influencing The Direction Of The Omics-Based Clinical Trials Market?
Leading entities within the omics lab services market are concentrating on crafting novel solutions, such as high-throughput genomics, to expedite biomedical research and the development of precision medicine. High-throughput genomics involves leveraging sophisticated technologies to swiftly sequence and analyze substantial quantities of DNA or RNA, thereby facilitating efficient large-scale genetic investigations. As an illustrative case, in September 2024, The Translational Genomics Research Institute (TGen), a US-based nonprofit medical research institution, established the Center for Spatial Multi-Omics (COSMO). This center delivers high-resolution whole-transcriptome data utilizing sequencing-based Visium HD alongside histological staining, and additionally provides tissue processing options like Tissue Microarray (TMA) construction for economical, multiplexed sample assessments. Its adaptable platforms, further improved by machine learning-driven cell segmentation, enable precise visualization and mapping of molecular information within preserved tissues, contributing to progress in precision medicine and disease understanding.
Who Are The Leading Firms Participating In The Omics-Based Clinical Trials Market?
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.
Access The Complete Omics-Based Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report
What Is The Largest Regional Market In The Omics-Based Clinical Trials Market?
North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Omics-Based Clinical Trials Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp
Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company
Medical And Diagnostic Laboratory Services Global Market Report 2026
Medical And Diagnostic Laboratory Services Global Market Report 2026
Lab Supplies Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model